Bright Minds Biosciences is a pre-revenue clinical-stage biotech developing drugs for neurological and psychiatric disorders. The company's lead program, BMB-101, is a selective 5-HT2C serotonin receptor agonist in Phase 2 trials targeting drug-resistant epilepsies, specifically Developmental and Epileptic Encephalopathies and Absence epilepsies. Bright Minds also plans a Phase 2 study of BMB-101 in Prader-Willi Syndrome, a rare genetic disorder, in 2026. Earlier-stage pipeline candidates include BMB-105 (also a 5-HT2C agonist targeting PWS), BMB-201 (a 5-HT2A/2C agonist for pain and psychiatry), and BMB-202 (a 5-HT2A agonist for psychiatry) — all in preclinical studies. The core scientific thesis is that Bright Minds' compounds selectively target specific serotonin receptor subtypes, avoiding the off-target effects and cardiac toxicity that limited older serotonergic drugs. Bright Minds has no revenue and funds operations through equity raises. The cost base is primarily clinical trial costs via contract research organizations, drug manufacturing through contract manufacturers, and a small internal headcount. Bright Minds holds an exclusive license to foundational patents from the University of Illinois Chicago and has filed its own patents on novel compounds. The eventual path to revenue runs through successful Phase 2 and Phase 3 trials, regulatory approval, and commercialization — either independently or via a partnership, licensing deal, or acquisition.